Medtronic PLC $MDT Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Key Points

• Mitsubishi UFJ Asset Management Co. Ltd. raised its Medtronic stake by 4.8% in Q4, buying 125,415 shares to hold 2,757,063 shares (~0.22%) valued at about $264.8 million.
• The stock carries a consensus rating of "Moderate Buy" with a $107.80 target, though analysts have recently issued mixed views and trimmed some price targets.
• Medtronic slightly beat Q-results (EPS $1.36 vs. $1.34, revenue $9.02B), set FY2026 guidance of $5.620–$5.660 EPS, and pays a $0.71 quarterly dividend (≈3.7% yield).

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,757,063 shares of the medical technology company's stock after purchasing an additional 125,415 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.22% of Medtronic worth $264,816,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in MDT. Brighton Jones LLC raised its position in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock worth $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC raised its position in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company's stock worth $380,000 after purchasing an additional 381 shares during the period. Jump Financial LLC acquired a new stake in shares of Medtronic during the 2nd quarter worth approximately $299,000. Main Street Financial Solutions LLC raised its position in shares of Medtronic by 28.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company's stock worth $1,251,000 after purchasing an additional 3,218 shares during the period. Finally, HUB Investment Partners LLC raised its position in shares of Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company's stock worth $1,676,000 after purchasing an additional 3,376 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Argus dropped their price target on Medtronic from $125.00 to $115.00 and set a "buy" rating on the stock in a research report on Monday, April 6th. Wall Street Zen cut Medtronic from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Sanford C. Bernstein raised their target price on Medtronic from $111.00 to $112.00 and gave the company an "outperform" rating in a research report on Friday, January 9th. Evercore set a $106.00 target price on Medtronic and gave the company an "outperform" rating in a research report on Thursday, April 9th. Finally, Daiwa Securities Group lowered their target price on Medtronic from $117.00 to $115.00 and set a "buy" rating on the stock in a research report on Friday, February 27th. Fifteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $107.80.

Medtronic Stock Performance

Shares of NYSE MDT opened at $77.77 on Wednesday. The stock has a fifty day moving average price of $88.06 and a two-hundred day moving average price of $94.68. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market cap of $99.85 billion, a P/E ratio of 21.66, a PEG ratio of 1.86 and a beta of 0.62. Medtronic PLC has a 1 year low of $77.39 and a 1 year high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic's dividend payout ratio (DPR) is presently 79.11%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic won a CE mark for its VitalFlow ECMO transport technology, expanding its critical-care portfolio in markets that accept CE certification — a direct commercial upside for its acute-care product lineup. Medtronic wins CE mark for VitalFlow ECMO transport tech
• Positive Sentiment: Medtronic emphasized momentum for the Affera cardiac arrhythmia franchise and noted a Breakthrough Device designation from FDA for related tech — this can accelerate trials, regulatory review and adoption, supporting medium-term growth in electrophysiology. Medtronic (MDT) Highlights Affera Momentum and FDA Breakthrough Device Designation
• Neutral Sentiment: Some analysts are recalibrating Medtronic’s fair value modestly (example: a trim from ~$109.08 to ~$108.00) and offering mixed views — this reflects divergence on how to value guidance and the pipeline rather than a consensus sell signal. How The Medtronic (MDT) Story Is Shifting As Guidance Meets Mixed Wall Street Views
• Neutral Sentiment: Competitive dynamics in diabetes devices continue to attract attention (analyst pieces on Dexcom and CGM market growth). A stronger CGM competitor landscape is a mixed influence: it validates market expansion but may pressure Medtronic’s share in certain segments. 3 Reasons Analysts Love DexCom (MDT)
• Negative Sentiment: Short-term selling pressure and session-to-session declines have shown up in market reports — coverage noting multi-percent drops over recent sessions is contributing to negative momentum and added volatility. Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Insider Transactions at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company's stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.26% of the company's stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.